| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| death D28 | 1.00 [0.92, 1.08] | | < 1 | | 5% | 16 studies (19/-) | 51.6 % | some concern | low | moderate | crucial | - |
| death or transfer to ICU | 1.09 [0.99, 1.20] | | < 1 | | 0% | 1 study (1/-) | 4.0 % | NA | not evaluable | | crucial | - |
| deaths | 0.98 [0.93, 1.03] | | < 1 | | 0% | 46 studies (71/-) | 82.5 % | some concern | critical | moderate | crucial | - |
| deaths (time to event analysis only) | 0.93 [0.83, 1.04] | | < 1 | | 48% | 12 studies (12/-) | 89.9 % | some concern | critical | moderate | crucial | - |
| clinical deterioration | 0.98 [0.74, 1.31] | | < 1 | | 27% | 10 studies (15/-) | 54.9 % | some concern | low | moderate | important | - |
| clinical improvement | 1.18 [1.01, 1.38] | | > 1 | | 55% | 16 studies (20/-) | 98.2 % | some concern | low | moderate | important | - |
| clinical improvement (14-day) | 1.07 [0.89, 1.27] | | > 1 | | 48% | 17 studies (17/-) | 76.1 % | some concern | low | moderate | important | - |
| clinical improvement (21-day) | 2.09 [0.04, 119.96] | | > 1 | | 0% | 1 study (1/-) | 63.7 % | NA | not evaluable | | important | - |
| clinical improvement (28-day) | 1.24 [1.03, 1.50] | | > 1 | | 54% | 9 studies (9/-) | 98.8 % | some concern | not evaluable | moderate | important | - |
| clinical improvement (7-day) | 1.20 [0.99, 1.45] | | > 1 | | 53% | 12 studies (14/-) | 97.1 % | some concern | critical | moderate | important | - |
| clinical improvement (time to event analysis only) | 1.22 [1.10, 1.36] | | > 1 | | 33% | 12 studies (15/-) | 100.0 % | some concern | low | moderate | important | - |
| death or ventilation | 1.02 [0.95, 1.10] | | < 1 | | 20% | 8 studies (8/-) | 28.5 % | some concern | not evaluable | moderate | important | - |
| hospital discharge | 0.98 [0.88, 1.08] | | > 1 | | 51% | 11 studies (15/-) | 31.0 % | some concern | low | moderate | important | - |
| hospitalization | 0.25 [0.08, 0.83] | | < 1 | | 0% | 2 studies (2/-) | 98.8 % | NA | not evaluable | | important | - |
| mechanical ventilation | 0.91 [0.73, 1.12] | | < 1 | | 37% | 18 studies (22/-) | 81.4 % | some concern | low | moderate | important | - |
| mechanical ventilation (time to event analysis only) | 0.06 [0.01, 0.83] | | < 1 | | 0% | 1 study (1/-) | 98.2 % | NA | not evaluable | | important | - |
| radiologic improvement (14-day) | 1.17 [0.42, 3.26] | | > 1 | | 16% | 3 studies (3/-) | 62.1 % | some concern | not evaluable | moderate | important | - |
| radiologic improvement (7-day) | 0.09 [0.01, 0.78] | | > 1 | | 0% | 2 studies (3/-) | 1.5 % | some concern | not evaluable | moderate | important | - |
| viral clearance | 1.47 [1.01, 2.13] | | > 1 | | 66% | 9 studies (14/-) | 97.7 % | some concern | serious | moderate | important | - |
| viral clearance (time to event analysis only) | 1.32 [1.03, 1.69] | | > 1 | | 0% | 2 studies (6/-) | 98.6 % | some concern | not evaluable | moderate | important | - |
| viral clearance by day 14 | 0.99 [0.93, 1.06] | | > 1 | | 0% | 8 studies (10/-) | 40.5 % | some concern | not evaluable | moderate | important | - |
| viral clearance by day 7 | 1.01 [0.84, 1.21] | | > 1 | | 28% | 8 studies (11/-) | 53.7 % | some concern | not evaluable | moderate | important | - |
| ICU admission | 0.91 [0.75, 1.10] | | < 1 | | 0% | 11 studies (13/-) | 84.2 % | some concern | low | moderate | non important | - |
| off oxygenation | 0.98 [0.64, 1.51] | | > 1 | | 0% | 1 study (1/-) | 46.4 % | NA | not evaluable | | non important | - |
| recovery | 1.09 [0.95, 1.26] | | > 1 | | 47% | 5 studies (5/-) | 89.0 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
| AE leading to drug discontinuation | 2.43 [0.79, 7.45] | | < 1 | | 0% | 1 study (1/-) | 6.0 % | NA | not evaluable | | important | - |
| cardiac arrest | 1.92 [0.35, 10.49] | | < 1 | | 0% | 1 study (1/-) | 22.7 % | NA | not evaluable | | important | - |
| related SAE (TRSAE) | 1.24 [0.50, 3.11] | | < 1 | | 0% | 1 study (1/-) | 32.0 % | NA | not evaluable | | important | - |
| serious adverse events | 0.85 [0.71, 1.01] | | < 1 | | 0% | 20 studies (21/-) | 96.5 % | some concern | low | moderate | important | - |
| abnormal ECG findings | 1.50 [0.88, 2.57] | | < 1 | | 0% | 1 study (-/1) | 7.0 % | NA | not evaluable | | non important | - |
| acute kidney injury | 1.18 [0.44, 3.18] | | < 1 | | 0% | 1 study (1/-) | 37.2 % | NA | not evaluable | | non important | - |
| adverse events | 1.78 [1.30, 2.42] | | < 1 | | 72% | 15 studies (21/-) | 0.0 % | some concern | low | moderate | non important | - |
| arrhythmia | 0.91 [0.72, 1.15] | | < 1 | | 0% | 3 studies (3/-) | 78.1 % | some concern | not evaluable | moderate | non important | - |
| deep vein thrombosis | 0.62 [0.23, 1.64] | | < 1 | | 0% | 2 studies (2/-) | 83.1 % | some concern | not evaluable | moderate | non important | - |
| elevated liver enzymes | 0.95 [0.29, 3.10] | | < 1 | | 84% | 3 studies (3/-) | 53.6 % | some concern | not evaluable | moderate | non important | - |
| hyperbilirubinemia | 0.97 [0.48, 1.93] | | < 1 | | 0% | 2 studies (2/-) | 53.8 % | low | not evaluable | high | non important | - |
| long QT | 2.39 [0.24, 23.87] | | < 1 | | 80% | 2 studies (2/-) | 23.0 % | some concern | not evaluable | moderate | non important | - |
| pulmonary embolism | 0.82 [0.20, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 61.1 % | some concern | not evaluable | moderate | non important | - |
| renal impairment | 1.26 [0.95, 1.67] | | < 1 | | 0% | 4 studies (4/-) | 5.6 % | some concern | not evaluable | moderate | non important | - |
| severe adverse events | 1.10 [0.07, 18.09] | | < 1 | | 0% | 2 studies (2/-) | 47.4 % | high | not evaluable | low | non important | - |
AE of interest endpoints 00 |
| Thromboembolic events | 0.89 [0.31, 2.55] | | < 1 | | 0% | 1 study (1/-) | 58.6 % | NA | not evaluable | | non important | - |
